Secondary squamous cell prostate cancer after prostate brachytherapy treatment.
Summary of "Secondary squamous cell prostate cancer after prostate brachytherapy treatment."
Abstract This report describes the case of a patient with prostate cancerat the age of 59 years, who was treated by interstitial prostate brachytherapy with iodine-125 seeds. Ten years later, he developed a probable secondary squamous cell cancer in his prostate.
Affiliation
Urological Clinics.
Journal Details
This article was published in the following journal.
Name: Scandinavian journal of urology and nephrology
ISSN: 1651-2065
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/21428844
- DOI: http://dx.doi.org/10.3109/00365599.2011.562237
Medical and Biotech [MESH] Definitions
Prostate-specific Antigen
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
Prostatic Secretory Proteins
Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.
Ultrasound, High-intensity Focused, Transrectal
Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).
Transurethral Resection Of Prostate
Removal of all or part of the PROSTATE, often using a cystoscope and/or resectoscope passed through the URETHRA.
Tissue Kallikreins
A family of trypsin-like SERINE ENDOPEPTIDASES that are expressed in a variety of cell types including human prostate epithelial cells. They are formed from tissue prokallikrein by action with TRYPSIN. They are highly similar to PROSTATE-SPECIFIC ANTIGEN. EC 3.4.21.35.
PubMed Articles
Precedence for prostate brachytherapy.
PURPOSE: To identify the earliest practitioners of prostate brachytherapy. METHODS AND MATERIALS: Review of contemporary literature. RESULTS: Radiotherapy has been used for benign prostatic ailments a...
Evolution of prostate cancer brachytherapy.
Curietherapy, more commonly named brachytherapy, is one of the oldest irradiation techniques used for prostate cancer. Prostate brachytherapy evolved according to the scientific and technological prog...
Quadrant dosimetry as a predictor of biochemical relapse in (125)I prostate brachytherapy.
Subacute penile numbness after brachytherapy for prostate cancer.
PURPOSE: Penile numbness is a rare complication of permanent prostate brachytherapy, and optimal clinical management remains unclear. We present such a case and discuss pathophysiology and clinical ma...
To assess a proper dose for radiation therapy fitting the typical physical characteristics of male Korean bodies, a mathematical phantom was prepared based on standard Korean male measurements. Upon b...
Clinical Trials
This research study is being done to collect regular and routine follow-up information related to the outcome of treatment for prostate cancer. This study is also being done to relate tre...
RATIONALE: Vitamin E supplements may stop or delay the development of prostate cancer in patients who are at risk of prostate cancer or who have prostate cancer. It is not yet known which...
The purpose of this clinical research study is to assess the safety and efficacy of an investigational therapy called DCVax(TM)-Prostate.
Primary: to investigate the effects of DNA repair gene polymorphisms on prostate cancer susceptibility, pathological grade, disease stage and clinical outcome Secondary: to understand the...
Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer
This study is for men who have prostate cancer that has spread outside of the prostate gland and is no longer responding to hormone removal therapy. This study is designed to determine if...
